CYP2C19 Genotype and Cardiovascular Events Reply

被引：1
|
作者：
Nissen, Steven E. [1 ]
机构：
[1] Cleveland Clin Fdn, Div Cardiovasc Med, Cleveland, OH 44195 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2012年 / 307卷 / 14期
关键词：
RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; ESTROGEN; RISK;
D O I：
10.1001/jama.2012.447
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1485 / 1485
页数：1
相关论文
共 50 条
  • [1] CYP2C19 Genotype and Cardiovascular Events
    Mega, Jessica L.
    Topol, Eric J.
    Sabatine, Marc S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (14): : 1482 - 1483
  • [2] CYP2C19 Genotype and Outcomes of Clopidogrel Treatment REPLY
    Pare, Guillaume
    Mehta, Shamir R.
    Eikelboom, John W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05): : 482 - 482
  • [3] Rapid CYP2C19 Genotype Testing: Comparison between Spartan RX CYP2C19 and Verigene CYP2C19
    Zhou, Y.
    Armstead, A. R.
    Coshatt, G. M.
    Brott, B. C.
    Sankaranarayanan, A.
    Limdi, N. A.
    Harada, S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 845 - 845
  • [4] CYP2C19 genotype: a moving target?
    Zembles, Tracy N.
    Marcuccilli, Charles J.
    Sander, Tara L.
    Simpson, Pippa
    PHARMACOTHERAPY, 2012, 32 (10): : E236 - E236
  • [5] CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis
    Holmes, Michael V.
    Perel, Pablo
    Shah, Tina
    Hingorani, Aroon D.
    Casas, Juan P.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (24): : 2704 - 2714
  • [6] The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel
    Tousoulis, Dimitris
    Siasos, Gerasimos
    Zaromitidou, Marina
    Oikonomou, Evangelos
    Maniatis, Konstantinos
    Kioufis, Stamatios
    Kokkou, Eleni
    Papavassiliou, Athanasios G.
    Stefanadis, Christodoulos
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (02) : 1594 - 1596
  • [7] Clopidogrel resistance in extremely high cardiovascular risk patients with genotype CYP2C19
    Cardenas, Liliana
    Aymen Abdullah, Ali
    Jaramillo, Gabriela
    Cardenas, Paul
    Galvez, Gabriela
    Hidalgo, Fernando
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2023, 52 (03): : 134 - 137
  • [8] CYP2C19 Genotype and Outcomes of Clopidogrel Treatment
    Siasos, Gerasimos
    Tousoulis, Dimitris
    Stefanadis, Christodoulos
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05): : 481 - 482
  • [9] CYP2C19 genotype and the PPIs - focus on rabeprazole
    Lim, PWY
    Goh, KL
    Wong, BCY
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 : S22 - S28
  • [10] Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole
    Klomp, Sylvia D.
    Veringa, Anette
    Alffenaar, Jan-Willem C.
    de Boer, Mark G. J.
    Span, Lambert F. R.
    Guchelaar, Henk-Jan
    Swen, Jesse J.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (07):
12345